Pathology CME

Credits: 1.50 CME / MOC / CC
Medical Learning Institute, Inc.
A Pan-Cancer, Pan-Biomarker Exploration of the Opportunities to Realize the Potential of Precision Immuno-Oncology: Are Pathology Professionals Ready for the Challenge?
Lynette M. Sholl, MD
23 October, 2019
Credits: 1.50 CME / MOC / CC
Medical Learning Institute, Inc.
Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Implications for Pathologists at the Forefront of the Emerging Precision Immuno-Oncology Era
Robert Anders, MD, PhD
1 May, 2019
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to the Clinical Role of TRK Fusions in Personalizing Cancer Therapy
Anna Farago, MD, PhD
7 February, 2019
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and Updated Guidelines: What Pathologists Need to Know and Do
Lynette M. Sholl, MD
6 February, 2019
Credits: 1.50 CME / MOC
Medical Learning Institute, Inc.
The Central Role of Biomarker Testing in Piecing Together the Immuno-Oncology Puzzle: Essential Guidance for Pathologists to Maximize the Potential of Cancer Immunotherapies
Robert Anders, MD, PhD
27 December, 2018
Credits: 1.50 CME / MOC
Medical Learning Institute, Inc.
Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do
Lynette Sholl, MD
11 December, 2018
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution
Kurt Schalper, MD, PhD / Edward B. Garon, MD, MS
30 November, 2018
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
Navigating the Complexities of Molecular Testing for EGFR Mutations to Guide Treatment Selection in Lung Cancer: Evidence, Practicalities, and Implications for Pathologists
Anjali Saqi, MD, MBA / Geoffrey R. Oxnard, MD
29 November, 2018
Credits: 1.50 CME / MOC / CE
Medical Learning Institute, Inc.
Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice
Edward Garon, MD, MS
22 November, 2018